Daiichi Sankyo Company, Limited: DESTINY-Lung04 Phase 3 Tria

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the first patient was dosed in the global DESTINY-Lung04 phase 3 trial evaluating the efficacy and safety of ENHERTU (trastuzumab

Related Keywords

United States , Japan , America , Nat Genet , Masashi Kawase , Ann Onc , Daiichi Sankyo , Daiichi Sankyo Europe Gmb , Don Murphy , Plexxikon Inc , Daiichi Sankyo Company , Oncology Development , Daiichi Sankyo Inc , World Health Organization , Clinical Development Program , Nasdaq , Sustainable Development Of Society , Daiichi Sankyo Co Ltd , Astrazeneca , International Agency For Research On Cancer , Innovative Global Healthcare Company , European Medicines Agency , Virtual Congress , Gilles Gallant , Senior Vice President , Global Head , New Drug Application , Interstitial Lung Disease , Prescribing Information , Development Program , Clinical Cancer Advances , Molecular Profiling Driving Progress , Breakthrough Therapy Designation , Astrazeneca Collaboration , Safety Information , Lung Disease Pneumonitis , Breast Cancer , Metastatic Gastric Cancer , Absolute Neutrophil Count , Ventricular Dysfunction , Fetal Toxicity , Dose Modifications , Adverse Reactions , Reproductive Potential , Global Healthcare Company Contributing , Sustainable Development , International Agency , Lung Fact , Accessed September , Cancer Non Small , Clin Oncol , Adv Med , Sankyo Europe Gmbh , Daiichi , Sankyo , Company , Imited , Destiny , Ung04 , Hase , Trial , Enhertu , Nitiated , Patients , Reviously , Untreated , Ther2 , Mutant , Metastatic , Mall , Fell , Young , Dancer ,